|
KMID : 0043320190420040305
|
|
Archives of Pharmacal Research
2019 Volume.42 No. 4 p.305 ~ p.318
|
|
|
Targeting tyrosine kinases for treatment of ocular tumors
|
|
Jo Dong-Hyun
Kim Jin-Hyoung
Kim Jeong-Hun
|
|
|
Abstract
|
|
|
|
Uveal melanoma is the most common intraocular primary malignant tumor in adults, and retinoblastoma is the one in children. Current mainstay treatment options include chemotherapy using conventional drugs and enucleation, the total removal of the eyeball. Targeted therapies based on profound understanding of molecular mechanisms of ocular tumors may increase the possibility of preserving the eyeball and the vision. Tyrosine kinases, which modulate signaling pathways regarding various cellular functions including proliferation, differentiation, and attachment, are one of the attractive targets for targeted therapies against uveal melanoma and retinoblastoma. In this review, the roles of both types of tyrosine kinases, receptor tyrosine kinases and non-receptor tyrosine kinases, were summarized in relation with ocular tumors. Although the conventional treatment options for uveal melanoma and retinoblastoma are radiotherapy and chemotherapy, respectively, specific tyrosine kinase inhibitors will enhance our armamentarium against them by controlling cancer-associated signaling pathways related to tyrosine kinases. This review can be a stepping stone for widening treatment options and realizing targeted therapies against uveal melanoma and retinoblastoma.
|
|
|
KEYWORD
|
|
|
Retinoblastoma, Uveal melanoma, Tyrosine kinase, Tyrosine kinase inhibitor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|